A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)

被引：0

作者：

Markman, B. ^{[1
]}

Solomon, B. ^{[2
]}

Nott, L. M. ^{[3
]}

Roberts-Thomson, R. ^{[4
]}

Hughes, B. ^{[5
]}

Pavlakis, N. ^{[6
]}

Davis, A. ^{[7
]}

Brown, L. J. ^{[8
]}

Parakh, S. ^{[9
]}

Brungs, D. ^{[10
]}

Bowyer, S. E. ^{[11
]}

Nordman, I. ^{[12
]}

Jennens, R. ^{[13
]}

Warburton, L. ^{[14
]}

Harris, S. J. ^{[15
]}

Samuel, E. ^{[16
]}

Ramanujam, S. ^{[17
]}

Wang, A. ^{[18
]}

Dumas, M. ^{[19
]}

Gard, G. ^{[19
]}

机构：

[1] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia

[2] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia

[3] Royal Hobart Hosp, Dept Med Oncol, Hobart, Tas, Australia

[4] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA, Australia

[5] Prince Charles Hosp, Canc Care Serv, Chermside, Qld, Australia

[6] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia

[7] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia

[8] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[9] Olivia Newton John Canc Res Inst, Med Oncol Dept, Heidelberg, Vic, Australia

[10] Wollongong Hosp, Dept Med Oncol, Illawarra Canc Ctr, Wollongong, NSW, Australia

[11] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia

[12] Calvary Mater Hosp Newcastle, Dept Med Oncol, Newcastle, NSW, Australia

[13] Peter MacCallum Canc Ctr, Med Oncol, East Melbourne, Vic, Australia

[14] Fiona Stanley Hosp, Dept Med Oncol, Perth, WA, Australia

[15] Bendigo Hlth, Ctr Canc, Bendigo, Vic, Australia

[16] Latrobe Reg Hosp, Med Oncol, Traralgon, Vic, Australia

[17] Griffith Base Hosp, Dept Med Oncol, Griffith, NSW, Australia

[18] Amgen Inc, CfOR, Sydney, NSW, Australia

[19] Walter & Eliza Hall Inst Med Res, Dept Oncol, Parkville, Vic, Australia

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.668

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

590P

引用

页码：S1700 / S1700

页数：1

共 50 条

[1] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
Pellini, B.
Ganesan, V.
Wan, F.
Sankararaman, S.
Manyanont, S.
Akhave, N.
Baggstrom, M.
Ward, J.
Waqar, S.
Morgensztern, D.
Govindan, R.
Devarakonda, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210
[2] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
Notario Rincon, L.
Pous, A.
Lopez-Paradis, A.
Cerda, G.
Cucurull, M.
Hernandez, A.
Domenech, M.
Carcereny, E.
Moran Bueno, M. T.
Munoz, A.
Mate, J. L.
Sanz, C.
Saigi, M.
ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
[3] Characteristics and treatment outcomes in advanced stage non-small cell lung cancer patients with KRAS G12C mutation
Illini, Oliver
Fabikan, Hannah
Hochmair, Maximilian J.
Weinlinger, Christoph
Krenbek, Dagmar
Brcic, Luka
Setinek, Ulrike
Terbuch, Angelika
Absenger, Gudrun
Konji, Selma
Valipour, Arschang
WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (19-20) : 727 - 728
[4] A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer
Iams, Wade
Balbach, Meridith L.
Phillips, Sharon
Sacher, Adrian
Bestvina, Christine
Velcheti, Vamsidhar
Wang, Xiao
Marmarelis, Melina E.
Sethakorn, Nan
Leal, Ticiana
Sackstein, Paul E.
Kim, Chul
Robinson, Andrew
Mehta, Kathan
Hsu, Robert
Nieva, Jorge
Patil, Tejas
Camidge, Ross
CLINICAL LUNG CANCER, 2023, 24 (03) : 228 - 234
[5] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
Hong, D. S.
Bang, Y. -J.
Barlesi, F.
Durm, G.
Falchook, G.
Govindan, R.
Dy, G.
Park, K.
Strickler, J.
Burns, T.
Kim, J.
Ang, A.
Lipford, J. R.
Ngarmchamnanrith, G.
Anderson, A.
Li, B. T.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
[6] KRAS G12C mutations in non-small cell lung cancer
Li, J. J.
Wu, X. J.
Farzin, M.
Bray, V.
Williamson, J.
Pal, A.
Yip, P. Y.
Hagelamin, A.
Ding, P.
Nindra, U.
Vinod, S.
French, B.
Chua, W.
Gupta, R.
Cooper, W. A.
Wang, B.
Lee, C. S.
HISTOPATHOLOGY, 2024, 85 : 25 - 25
[7] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Pinto, L. Masfarre
Parreira, A. S. D. F. M.
Unanua, N. Castro
Rocha, P.
Ruiz, I. Morilla
Sanchez, L. Teijeira
Clave, S.
Gorro, N. Navarro
Mora, R. Bach
Sanchez, I.
Campos, M. A. Galindo
Garcia, A. Taus
Martinez, A. Azkarate
Fabregat, R. Marse
Paricio, B. Bellosillo
Arasanz, H.
Aguillo, M. Martinez
Arriola, E.
ANNALS OF ONCOLOGY, 2023, 34
[8] Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Girard, N.
Perol, M.
Debieuvre, D.
Bosquet, L.
Veillard, C.
Caillon, M.
Tzala, L.
Desamericq, G.
Valette, C. Audigier
ANNALS OF ONCOLOGY, 2023, 34
[9] Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)
De Renzi, G.
Nicolazzo, C.
Pisegna, S.
Belardinilli, F.
Bottillo, I.
Grammatico, P.
Giannini, G.
Gelibter, A. J.
Gazzaniga, P.
ANNALS OF ONCOLOGY, 2021, 32 : S983 - S983
[10] KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer.
Qian, David
Behera, Madhusmita
Steuer, Conor Ernst
Pakkala, Suchita
Carlisle, Jennifer W.
Owonikoko, Taofeek Kunle
Fischer-Valuck, Benjamin Walker
Kesarwala, Aparna Hemant
Bradley, Jeffrey
Curran, Walter J.
Ramalingam, Suresh S.
Higgins, Kristin Ann
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →